Evaluating the safety of influenza vaccine using a claims-based health system
- PMID: 24148577
- PMCID: PMC6688603
- DOI: 10.1016/j.vaccine.2013.10.031
Evaluating the safety of influenza vaccine using a claims-based health system
Abstract
Introduction: As part of the Centers for Disease Control and Prevention's monitoring and evaluation activities for influenza vaccines, we examined relationships between influenza vaccination and selected outcomes in the 2009-2010 and 2010-2011 influenza seasons in a claims-based data environment.
Methods: We included patients with claims for trivalent influenza vaccine (TIV) and/or 2009 pandemic influenza A H1N1 vaccine (H1N1) during the 2009-2010 and 2010-2011 influenza seasons. Patients were followed for several pre-specified outcomes identified in claims. Seizures and Guillain-Barré Syndrome were selected a priori for medical record confirmation. We estimated incidence rate ratios (IRR) using a self-controlled risk interval (SCRI) or a historical comparison design. Outcomes with elevated IRRs, not selected a priori for medical record review, were further investigated with review of claims histories surrounding the outcome date to determine whether the potential event could be ruled-out or attributed to other causes based on the pattern of medical care.
Results: In the 2009-2010 season, no significant increased risks for outcomes following H1N1 vaccination were observed. Following TIV administration, the IRR for peripheral nervous system disorders and neuropathy was slightly elevated (1.07, 95% CI: 1.01-1.13). The IRR for anaphylaxis following TIV was 28.55 (95% CI: 3.57-228.44). After further investigation of claims histories, the majority of potential anaphylaxis cases had additional claims around the time of the event indicating alternate explanatory factors or diagnoses. In the 2010-2011 season following TIV administration, a non-significant elevated IRR for anaphylaxis was observed with no other significant outcome findings.
Conclusion: After claims history review, we ultimately found no increased outcome risk following administration of 998,881 TIV and 538,257 H1N1 vaccine doses in the 2009-2010 season, and 1,158,932 TIV doses in the 2010-2011 season.
Keywords: Claims; H1N1; Influenza; Vaccine safety.
Published by Elsevier Ltd.
Similar articles
-
Surveillance for Guillain-Barré syndrome after 2015-2016 and 2016-2017 influenza vaccination of Medicare beneficiaries.Vaccine. 2019 Oct 8;37(43):6543-6549. doi: 10.1016/j.vaccine.2019.08.045. Epub 2019 Sep 9. Vaccine. 2019. PMID: 31515146
-
Safety assessment of seasonal trivalent influenza vaccine produced by Instituto Butantan from 2013 to 2017.Rev Inst Med Trop Sao Paulo. 2018 Dec 20;61:e4. doi: 10.1590/S1678-9946201961004. Rev Inst Med Trop Sao Paulo. 2018. PMID: 30570077 Free PMC article. Review.
-
Events supposedly attributable to vaccination or immunization during pandemic influenza A (H1N1) vaccination campaigns in Latin America and the Caribbean.Vaccine. 2015 Jan 1;33(1):187-92. doi: 10.1016/j.vaccine.2014.10.070. Epub 2014 Nov 6. Vaccine. 2015. PMID: 25444798
-
Absence of associations between influenza vaccines and increased risks of seizures, Guillain-Barré syndrome, encephalitis, or anaphylaxis in the 2012-2013 season.Pharmacoepidemiol Drug Saf. 2014 May;23(5):548-53. doi: 10.1002/pds.3575. Epub 2014 Feb 4. Pharmacoepidemiol Drug Saf. 2014. PMID: 24497128
-
Guillain-Barré syndrome and H1N1 (2009) pandemic influenza vaccination using an AS03 adjuvanted vaccine in the United Kingdom: self-controlled case series.Vaccine. 2011 Oct 19;29(45):7878-82. doi: 10.1016/j.vaccine.2011.08.069. Epub 2011 Aug 27. Vaccine. 2011. PMID: 21875631
Cited by
-
Population-Based Incidence of Guillain-Barré Syndrome During Mass Immunization With Viral Vaccines: A Pooled Analysis.Front Immunol. 2022 Feb 3;13:782198. doi: 10.3389/fimmu.2022.782198. eCollection 2022. Front Immunol. 2022. PMID: 35185881 Free PMC article.
-
Is an Increased Risk of Developing Guillain-Barré Syndrome Associated with Seasonal Influenza Vaccination? A Systematic Review and Meta-Analysis.Vaccines (Basel). 2020 Mar 27;8(2):150. doi: 10.3390/vaccines8020150. Vaccines (Basel). 2020. PMID: 32230964 Free PMC article. Review.
-
Gulllain-Barre Syndrome After Trivalent Influenza Vaccination in Adults.Front Neurol. 2019 Jul 24;10:768. doi: 10.3389/fneur.2019.00768. eCollection 2019. Front Neurol. 2019. PMID: 31396144 Free PMC article.
-
Psychosis with Methylphenidate or Amphetamine in Patients with ADHD.N Engl J Med. 2019 Mar 21;380(12):1128-1138. doi: 10.1056/NEJMoa1813751. N Engl J Med. 2019. PMID: 30893533 Free PMC article.
-
Development and application of two semi-automated tools for targeted medical product surveillance in a distributed data network.Curr Epidemiol Rep. 2017 Dec;4(4):298-306. doi: 10.1007/s40471-017-0121-0. Epub 2017 Oct 6. Curr Epidemiol Rep. 2017. PMID: 29204333 Free PMC article.
References
-
- Haber P, DeStefano F, Angulo FJ, Iskander J, Shadomy SV, Weintraub E, et al. Guillain–Barré syndrome following influenza vaccination. Journal of the American Medical Association 2004;292(November (20)):2478–81. - PubMed
-
- McMahon AW, Iskander J, Haber P, Chang S, Woo EJ, Braun MM, et al. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990–2003. Pediatrics 2005;115(February (2)):453–60. - PubMed
-
- Zhou W, Pool V, DeStefano F, Iskander JK, Haber P, Chen RT, et al. A potential signal of Bell’s palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS)—United States, 1991–2001. Pharmacoepidemiology and Drug Safety 2004;13(August (8)):505–10. - PubMed
-
- Jann MW, Fidone GS. Effect of influenza vaccine on serum anticonvulsant concentrations. Clinical Pharmacy 1986;5(October (10)):817–20. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials